Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer, FDA and hemophilia B
Pfizer’s Hympavzi Approved for Treatment of Certain Types of Hemophilia
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a week.
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for constant intravenous infusions or injections, which are painful as well as inconvenient.
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi,
FDA Approves Hympavzi for Hemophilia A and B
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age 12 or older with hemophilia A or B without inhibitors (neutralizing antibodies), according to a news release published today.
US FDA approves Pfizer's drug for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.
FDA approves marstacimab, now Hympavzi, for hemophilia
The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, without inhibitors.
FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.
USFDA approves Pfizer's Hympavzi for rare bleeding disorder hemophilia
The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors,
FDA Approves Pfizer's Hympavzi for Hemophilia A, B
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
FDA approves first once-weekly drug treatment regimen for hemophilia
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first once-weekly treatment for the disease.
Business Insider
1h
FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents
(RTTNews) -
Pfizer
Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved
HYMPAVZI
(marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of ...
devdiscourse
6h
Global Health Issues Develop Amidst Breakthroughs and Concerns
Recent health developments include HIV infections from organ transplants in Brazil, Sanofi's potential sale of a stake in its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Indicted on 6 felony counts
How to help Milton victims
Admonishes Black men
Man attacked, killed by dogs
Carne asada drug bust
Drownings were avoidable?
Gators displaced by Milton
To close 444 stores
Russia cements ties with Iran
Gets Walk of Fame star
Nobel Peace Prize awarded
Gets 2 years for role in riot
CA rejects SpaceX plan
US consumer sentiment slips
JPMorgan says soft landing
Coast Guard rescues man
Assets hit $11.5 trillion
Files suit against Virginia
Meets Zelenskyy at Vatican
Drug for hemophilia approved
Judge scrutinizes plea deal
Toyota returns to Formula 1
US producer prices flat
Calls for relief funding
Settles kickback allegations
Fidelity data breach
Loses bid to get on PA ballot
NBA star Green retires
To cut workforce by 10%
Adds 8 new destinations
Feedback